THMO (Cesca Therapeutics) יחס יתרת חוב לטווח ארוך להון

ThermoGenesis (THMO) generates revenue from the supply of cryopreservation and cell separation systems, securing a reliable cash flow from services and the sale of consumables. This price chart (separate_debt_long_eq) reflects the dynamics of the indicator, which currently stands at 2.85. The business stability is underpinned by US-based plants producing equipment for regenerative therapy and the sterile processing of biomaterials.

For an investor in ThermoGenesis (THMO) innovations, this indicator determines the stability of the funding structure for regenerative medicine development. The long-term debt-to-equity ratio is calculated as the ratio of liabilities with a maturity exceeding one year to shareholders' equity. An increase in this metric on the chart signals an increase in financial leverage. An optimal leverage balance is critical for scaling automated biobanking systems. A low debt load confirms the fundamental reliability of the business.